C
Chunhao Yang
Researcher at Chinese Academy of Sciences
Publications - 116
Citations - 1191
Chunhao Yang is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Alkyl & Cascade reaction. The author has an hindex of 18, co-authored 109 publications receiving 984 citations. Previous affiliations of Chunhao Yang include Guangzhou University & Georgia State University.
Papers
More filters
Journal ArticleDOI
Synthesis and activity of Combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents.
TL;DR: A series of 4,5-disubstitute-1,2,3-thiadiazole compounds were designed and synthesized as potent anticancer agents and some of them exhibited excellent in vitro and in vivo inhibitory activity.
Journal ArticleDOI
Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics
TL;DR: This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.
Journal ArticleDOI
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.
Yiyue Ge,Tingzhong Tian,Huang S,Fangping Wan,Jingxin Li,Shuya Li,Wang X,Hui Yang,Lixiang Hong,Nian Wu,Enming Yuan,Yunan Luo,Lili Cheng,Chengliang Hu,Yipin Lei,Hantao Shu,Xiaolong Feng,Ziyuan Jiang,Yunfu Wu,Ying Chi,Xiling Guo,Lunbiao Cui,Liang Xiao,Zeng Li,Chunhao Yang,Zehong Miao,Ligong Chen,Ligong Chen,Haitao Li,Hainian Zeng,Dan Zhao,Fengcai Zhu,Fengcai Zhu,Xiaokun Shen,Jianyang Zeng +34 more
TL;DR: Wang et al. as discussed by the authors developed an integrative drug repositioning framework, which fully takes advantage of machine learning and statistical analysis approaches to systematically integrate and mine large-scale knowledge graph, literature and transcriptome data to discover the potential drug candidates against SARS-CoV-2.
Journal ArticleDOI
S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
Chao Zhang,Na Yang,Chunhao Yang,Hua-sheng Ding,Cheng Luo,Yu Zhang,Mao-jiang Wu,Xiong-Wen Zhang,Xu Shen,Xu Shen,Hualiang Jiang,Hualiang Jiang,Linghua Meng,Jian Ding +13 more
TL;DR: Taken together, S9 targets both PI3K-Akt-mTOR signaling and microtubule cytoskeleton, which combinatorially contributes its antitumor activity and provides new clues for anticancer drug design and development.
Journal Article
Abstract #3391: S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton
Chao Zhang,Na Yang,Chunhao Yang,Hua-sheng Ding,Cheng Luo,Yu Zhang,Mao-jiang Wu,Xiong-Wen Zhang,Xu Shen,Hualiang Jiang,Linghua Meng,Jian Ding +11 more
TL;DR: In this article, S9, a hybrid of methylene and 2-phenyl indole compound, was found to abrogate EGF-activated PI3K-Akt-mTOR signaling cascade and Akt translocation to cellular membrane.